The company said in a news release that this marks the first FDA-cleared, AI-powered solution for detecting and triaging suspected AAA.
Viz.ai’s AI algorithm automatically searches for the presence of an abdominal aortic aneurysm from any computed tomography angiography (CTA) scan. These chest cans can come from any scanner within a hospital network. Viz.ai said this algorithm comprises part of its Viz Aortic Module. The company designed this AI solution to accelerate treatment decisions for all aortic pathology.
Dr. Philip Batista, associated program director of vascular and endovascular surgery residency at Cooper, said the majority of AAA patients are asymptomatic. Many remain unaware of their disease until a rupture occurs, he noted.
“This is a catastrophic medical emergency, resulting in over 10,000 deaths each year,” said Batista. “This algorithm is a powerful new tool for healthcare professionals to more readily identify and capture individuals with AAA and, importantly, automatically refer those at imminent risk for rupture.”
Viz.ai said it plans to work with leading hospitals and providers to implement Viz AAA into clinical workflows. It also intends to continue expanding its healthcare offerings.
“AAA is an important and actionable incidental finding that is too often missed,” said Jayme Strauss, chief clinical officer at Viz.ai. “The vision behind Viz AAA is to automatically catch and follow abdominal aortic disease, no matter the patient’s location. We believe that this product will enable care teams to prevent catastrophic aortic emergencies, such as aortic rupture, by increasing the surveillance of these patients.”
